Fatal or nonfatal myocardial infarction · participants with UA/NSTEMI in the stent era
Routine invasive strategies showed no clear difference in death or non‐fatal Myocardial infarction compared with selective invasive strategies (conservative) (low certainty).
1 finding from 1 review
Refractory angina · participants with UA/NSTEMI in the stent era
Routine invasive strategies probably leads to lower refractory angina compared with selective invasive strategies (conservative) (moderate certainty).
1 finding from 1 review
Patient readmissions · participants with UA/NSTEMI in the stent era
Routine invasive strategies probably leads to lower rehospitalisation compared with selective invasive strategies (conservative) (moderate certainty).
1 finding from 1 review
Complications of angiography or revascularization Bleeding · participants with UA/NSTEMI in the stent era
Routine invasive strategies probably leads to higher complications of angiography or revascularization Bleeding compared with selective invasive strategies (conservative) (moderate certainty).
1 finding from 1 review
Complications of angiography or revascularization Procedure‐related myocardial infarction · participants with UA/NSTEMI in the stent era
Routine invasive strategies probably leads to higher complications of angiography or revascularization Procedure‐related… compared with selective invasive strategies (conservative) (moderate certainty).
1 finding from 1 review
Maternal death · patients with sickle cell disease in pregnancy
1 finding from 1 review
Severe maternal morbidity (pulmonary embolism) · patients with sickle cell disease in pregnancy
1 finding from 1 review
Severe maternal morbidity (congestive cardiac failure) · patients with sickle cell disease in pregnancy
It is very uncertain whether prophylactic changes severe maternal morbidity (congestive cardiac failure) compared with selective blood transfusion (very low certainty).
1 finding from 1 review
Perinatal mortality · patients with sickle cell disease in pregnancy
It is very uncertain whether prophylactic changes perinatal death compared with selective blood transfusion (very low certainty).
1 finding from 1 review
Sickle cell crisis (pain crisis) · patients with sickle cell disease in pregnancy
Prophylactic may leads to lower sickle cell crisis (pain crisis) compared with selective blood transfusion (low certainty).
1 finding from 1 review
Sickle cell crises (acute splenic sequestration) · patients with sickle cell disease in pregnancy
Prophylactic showed no clear difference in sickle cell crises (acute splenic sequestration) compared with selective blood transfusion (low certainty).
1 finding from 1 review
Blood transfusion reaction · patients with sickle cell disease in pregnancy
It is very uncertain whether prophylactic changes blood transfusion reaction compared with selective blood transfusion (very low certainty).
1 finding from 1 review
Intervention not reported
Breast cancer mortality ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence ‐ AIs · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Prevention: incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor) or not receiving endocrine therapy…
1 finding from 1 review